Profile picture

Professor Zanfina Ademi

Monash University, Melbourne (Australia)
Follow
Biography
Professor Zanfina Ademi leads a program of research around prevention of cardiovascular disease, population genomics, epilepsy management and other health conditions. She also leads a program of research on the Productivity Adjusted Life Years (PALYs), which aim to quantify productivity loss at population level and incorporate productivity explicitly in decision making. She specialises in Health Technology Assessments (HTAs), economic evaluations alongside clinical trials and clinical registries and decision health economic modelling. She has worked in Australia, Finland and Switzerland, leading funded research projects that have provided evidence on cost-effectiveness and return on investment enabling key decision-makers (governments, payers) to enact effective healthcare funding across the world. Currently, she serves in a number of reputable international committees with translational impact, such as the Economics Sub-Committee (ESC) of Australia’s Pharmaceutical Benefit Schemes
Logo ESC

Contributor content

Early lowering of LDL-C is a more cost-effective strategy than lowering LDL-C later in life: a cost-effectiveness analysis using Mendelian Randomisation
Presentation
Early lowering of LDL-C is a more cost-effective strategy than lowering LDL-C later in life: a cost-effectiveness analysis using Mendelian Randomisation
Dutch Nationwide Implementation Program for familial hypercholesterolemia case finding in children: a cost-effectiveness and return on investment analysis
Presentation
Dutch Nationwide Implementation Program for familial hypercholesterolemia case finding in children: a cost-effectiveness and return on investment analysis
Population genomic screening of all young adults in Australia to detect familial hypercholesterolemia: a cost-effectiveness analysis
Presentation
Population genomic screening of all young adults in Australia to detect familial hypercholesterolemia: a cost-effectiveness analysis
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?
Presentation
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?
Presentation
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?

ESC 365 is supported by